Live Updates: COVID-19 Cases
  • World 21,108,478
    World
    Confirmed: 21,108,478
    Active: 6,394,815
    Recovered: 13,955,549
    Death: 758,114
  • USA 5,418,045
    USA
    Confirmed: 5,418,045
    Active: 2,403,349
    Recovered: 2,844,250
    Death: 170,446
  • Brazil 3,229,621
    Brazil
    Confirmed: 3,229,621
    Active: 767,417
    Recovered: 2,356,640
    Death: 105,564
  • India 2,465,662
    India
    Confirmed: 2,465,662
    Active: 663,755
    Recovered: 1,753,719
    Death: 48,188
  • Russia 912,823
    Russia
    Confirmed: 912,823
    Active: 174,361
    Recovered: 722,964
    Death: 15,498
  • South Africa 572,865
    South Africa
    Confirmed: 572,865
    Active: 123,978
    Recovered: 437,617
    Death: 11,270
  • Peru 507,996
    Peru
    Confirmed: 507,996
    Active: 134,342
    Recovered: 348,006
    Death: 25,648
  • Mexico 505,751
    Mexico
    Confirmed: 505,751
    Active: 108,951
    Recovered: 341,507
    Death: 55,293
  • Chile 380,034
    Chile
    Confirmed: 380,034
    Active: 16,604
    Recovered: 353,131
    Death: 10,299
  • Spain 355,856
    Spain
    Confirmed: 355,856
    Active: 327,251
    Recovered: ?
    Death: 28,605
  • Iran 338,825
    Iran
    Confirmed: 338,825
    Active: 25,683
    Recovered: 293,811
    Death: 19,331
  • UK 313,798
    UK
    Confirmed: 313,798
    Active: 272,451
    Recovered: ?
    Death: 41,347
  • Saudi Arabia 295,902
    Saudi Arabia
    Confirmed: 295,902
    Active: 29,605
    Recovered: 262,959
    Death: 3,338
  • Pakistan 287,300
    Pakistan
    Confirmed: 287,300
    Active: 15,932
    Recovered: 265,215
    Death: 6,153
  • Bangladesh 271,881
    Bangladesh
    Confirmed: 271,881
    Active: 111,667
    Recovered: 156,623
    Death: 3,591
  • Italy 252,235
    Italy
    Confirmed: 252,235
    Active: 14,081
    Recovered: 202,923
    Death: 35,231
  • Turkey 245,635
    Turkey
    Confirmed: 245,635
    Active: 11,666
    Recovered: 228,057
    Death: 5,912
  • Germany 222,269
    Germany
    Confirmed: 222,269
    Active: 12,188
    Recovered: 200,800
    Death: 9,281
  • France 209,365
    France
    Confirmed: 209,365
    Active: 95,505
    Recovered: 83,472
    Death: 30,388
  • Canada 121,234
    Canada
    Confirmed: 121,234
    Active: 4,666
    Recovered: 107,553
    Death: 9,015
  • China 84,786
    China
    Confirmed: 84,786
    Active: 690
    Recovered: 79,462
    Death: 4,634
  • Netherlands 61,840
    Netherlands
    Confirmed: 61,840
    Active: 55,673
    Recovered: ?
    Death: 6,167
  • Australia 22,743
    Australia
    Confirmed: 22,743
    Active: 9,018
    Recovered: 13,350
    Death: 375
  • S. Korea 14,873
    S. Korea
    Confirmed: 14,873
    Active: 705
    Recovered: 13,863
    Death: 305
  • New Zealand 1,602
    New Zealand
    Confirmed: 1,602
    Active: 49
    Recovered: 1,531
    Death: 22

COVID-19: Top US doctor Fauci cautiously optimistic over vaccine development by early 2021

Author at TechGenyz Health
Vaccine Development
@Gustavo Fring | Pexels

America’s top infectious disease expert Dr. Anthony Fauci has said that he is cautiously optimistic over the results from the current clinical trials and the possibility of developing a vaccine for COVID-19 by the end of this year or early next year.

Fauci, the National Institute of Allergy and Infectious Diseases Director, said that the coronavirus will likely to continue to emerge, and global collaboration and transparency are critical to deal with the future pandemics.

“The lessons we’ve learned from the coronavirus is they have pandemic potential, they’re likely to continue to emerge. Good public health measures are critical to controlling them.

Global collaboration and transparency are critical if we are to get a containment of this extraordinary assault on the human population, a viral disease that spreads rapidly and as a high degree of morbidity and mortality, he said in his recorded remarks during an online session on Confronting COVID-19 Through Innovation and Research: Lessons Learned from the Pandemic’.

The event is part of a series of online dialogue by the United Nations Academic Impact (UNAI) dubbed ’75 for UN75: 75 Minutes of Conversation’ that brings together academics, researchers and students from around the world.

Giving an overview of the pandemic and efforts to develop a vaccine, Fauci said: we’ve adopted a strategic approach to getting multiple candidates and there is more than one candidate vaccine to be conducted in trials in a harmonized way so that we use standard endpoints, standard and single data, and safety monitoring board as well as identical immunological parameters that are measured so that you could bridge one study to another.

There are a number of vaccine candidates already in a clinical trial and a few out of those candidates have completed phase 1/2 status, he said, adding that there are trials that will be going into phase three sometime at the end of July and then others will follow in the months of August, September, and October.

Fauci said hopefully we’ll be able to get some information, such as with this particular one representative vaccine that we started here in January. Phase one looks good, very promising data on the induction of neutralizing antibody and will go into the trial at the end of July.

There are 5-7 candidates that are going into clinical trials at different stages, he said.

The Moderna coronavirus vaccine is showing promising results, “which makes me cautiously optimistic. Although you can never, ever predict with any certainty, whether a vaccine is going to be safe and effective.

The early data on these trials have cautious optimism that we will be successful at least in developing a vaccine with some degree of efficacy by the end of the year, beginning of 2021, he said.

Moderna said that it has completed enrollment of Phase 2 Study of its mRNA vaccine against COVID-19, adding that it has finalized the Phase 3 study protocol based on the feedback from the US Food and Drug Administration (FDA).

The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases, subject to regulatory approval.

Moderna has completed the manufacture of vaccine required to start the Phase 3 study and the company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year beginning in 2021 from the company’s internal US manufacturing site and strategic collaborations, the biotechnology company added.

According to Johns Hopkins Coronavirus Resource Center, the contagion has infected over 12 million people and killed more than 549,000 across the world.

The US is the worst affected country with over 3 million cases and more than 1,32,000 deaths.

The COVID-19, which originated in China’s Wuhan city in December last year, has also battered the world economy with the International Monetary Fund saying that the global economy is bound to suffer a “severe recession”.

Scientists are racing against time to find a vaccine or medicine for its treatment.

Career

Subscribe